Probenecid

Generic Name: Probenecid

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₉NO_₄S

CAS Number: 57-66-9

Unique Ingredient Identifier: PO572Z7917

Background: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.

Indication: For the reduction of serum uric acid concentrations in chronic gouty arthritis and tophaceous gout in patients with frequent disabling gout attacks. Has also been effectively used to promote uric acid excretion in hyperuricemia secondary to the administration of thiazide and related diuretics.

Associated Conditions: Bacterial Infections, Chronic Gouty Arthritis, Elevated Serum Uric Acid, Gout Chronic, Hyperuricemia, Infection

Associated Therapies: -

Clinical Trials

Probenecid as Medication for Alcohol Use Disorder

Phase 1

Completed

Conditions: Alcohol Use Disorder

Interventions: Drug: Matching placebo
Drug: Probenecid

First Posted Date: 2020-01-06

Last Posted Date: 2024-03-26

Lead Sponsor: Brown University

Target Recruit Count: 34

Registration Number: NCT04218357

Locations: 🇺🇸
Brown University, Providence, Rhode Island, United States

TRPV2 Agonists in the Fontan Circulation

Phase 4

Completed

Conditions: Fontan

Interventions: Drug: Probenecid
Other: Placebo

First Posted Date: 2019-05-29

Last Posted Date: 2021-07-09

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 8

Registration Number: NCT03965351

Locations: 🇺🇸
Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States

A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04965842
Drug: Probenecid

First Posted Date: 2019-05-03

Last Posted Date: 2019-10-18

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT03937258

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin

Phase 1

Completed

Conditions: Drug Interaction Potentiation

Interventions: Drug: vadadustat
Drug: Cyclosporins
Drug: Probenecid
Drug: Rifampin

First Posted Date: 2019-01-11

Last Posted Date: 2019-03-22

Lead Sponsor: Akebia Therapeutics

Target Recruit Count: 40

Registration Number: NCT03801746

Locations: 🇨🇦
inVentiv Health Clinique Inc., Québec City, Quebec, Canada

A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide
Drug: Probenecid
Drug: Ciclosporin

First Posted Date: 2018-03-15

Last Posted Date: 2019-06-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21

Registration Number: NCT03466567

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin
Drug: Furosemide
Drug: Probenecid
Drug: Metformin
Drug: Rosuvastatin
Drug: Cimetidine
Drug: Verapamil
Drug: Rifampin

First Posted Date: 2017-10-11

Last Posted Date: 2023-11-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 45

Registration Number: NCT03307252

Locations: 🇩🇪
CTC North GmbH & Co. KG, Hamburg, Hamburg, Germany

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Bexagliflozin
Drug: Probenecid
Drug: Rifampin
Drug: Verapamil

First Posted Date: 2017-09-28

Last Posted Date: 2021-07-01

Lead Sponsor: Theracos

Target Recruit Count: 48

Registration Number: NCT03296800

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

Effect of Probenecid on Pexidartinib Pharmacokinetics

Phase 1

Completed

Conditions: Pharmacokinetics in Healthy Volunteers

Interventions: Drug: Pexidartinib
Drug: Probenecid

First Posted Date: 2017-05-03

Last Posted Date: 2017-05-03

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 16

Registration Number: NCT03138759

Locations: 🇺🇸
Worldwide Clinical Trials Early Phase Services, San Antonio, Texas, United States

A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-64041575
Drug: Probenecid

First Posted Date: 2017-04-10

Last Posted Date: 2018-08-13

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 18

Registration Number: NCT03105986

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

Effect of Probenecid on Synovial Fluid ATP Levels in CPPD

Early Phase 1

Completed

Conditions: Calcium Pyrophosphate Deposition Disease

Interventions: Drug: Probenecid

First Posted Date: 2014-09-18

Last Posted Date: 2022-07-26

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 8

Registration Number: NCT02243631

Locations: 🇺🇸
Clement J. Zablocki VA Medical Center, Milwaukee, WI, Milwaukee, Wisconsin, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy